Amylin has lower sales, higher costs as it ramps up Bydureon sales
This article was originally published in Scrip
Amylin Pharmaceuticals focused on sales of its once-weekly type 2 diabetes drug Bydureon (exenatide) rather than prospective buyers or investor lawsuits during its first quarter 2012 earnings call during which it reported a revenue decline despite its recent product launch. The company attributed the higher net loss to the cost of ramping up sales for Bydureon, which generated $6.9 million in revenue during its first-ever quarter of sales.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.